AbbVie Q3 adjusted EPS $1.86 (down 38%), revenue up 9.1%; raises FY25 guidance; dividend up 5.5%

AbbVie Inc.

2025-Q3 EPS reported $1.34 vs consensus $1.81 ▼ miss (-26.0%)

GAAP diluted EPS $0.10 (down 88.6%); adjusted diluted EPS $1.86 (down 38%); includes $1.50/share unfavorable impact from acquired IPR&D.
Net revenues $15.776B, up 9.1% reported (8.4% operational); Immunology $7.885B (+11.9%) led by Skyrizi $4.708B (+46.8%).
Raises 2025 adjusted diluted EPS guidance to $10.61-$10.65 (from $10.38-$10.58); includes $2.05/share YTD IPR&D impact.
Quarterly dividend increased 5.5% to $1.73/share, payable Feb 17, 2026 to holders of record Jan 16, 2026.
Oncology $1.682B (-0.3%); Aesthetics $1.193B (-3.7%); Neuroscience $2.841B (+20.2%); Vraylar $934M, Botox Therapeutic $985M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.